CD274 and neoplasm: Notably, patients with positive tumour PD-L1 expression (i.e. combined positive score [CPS] ≥ 10) or LN-only disease had more favourable treatment outcomes with pembrolizumab (ORRs, 47.3% and 49.0%; median OS, 18.5 months and 27.0 months, respectively) (66).